An update on childhood urticaria and angioedema

Bailey, Evan; Shaker, Marcus

doi:10.1097/mop.0b013e328305e262

Cited by 41 publications

(27 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Podejście dia gnostyczne w stosunku do przyczyn PPS w pediatrii nie powinno się różnić od schematu obowiązującego u dorosłych [71][72][73], z wyjątkiem może niemowląt [74]. Istnieją natomiast różnice pomiędzy dziećmi i dorosłymi w zakresie częstości występowania okreś lonych przyczyn choroby [75].…”

Section: Rozpoznawanie Pokrzywki U Dzieciunclassified

The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update

Zuberbier¹,

Aberer²,

Asero³

et al. 2015

View full text Add to dashboard Cite

Section: Rozpoznawanie Pokrzywki U Dzieciunclassified

The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update

Zuberbier¹,

Aberer²,

Asero³

et al. 2015

View full text Add to dashboard Cite

“…Bailey and Shaker in a review on update on childhood urticaria and angioedema concluded that long-term corticosteroids therapy and other immunomodulating agents such as omalizumab need an understanding of the adjustments between potential risks and expected benefits of the therapy, evaluating possible side effects of therapy against the natural history of underlying disease and consultation for decision making was recommended in cases of severe refractory CIU in which immunomodulators or monoclonal antibody therapy is considered (52).…”

Section: Omalizumab In Children With Chronic Urticariamentioning

confidence: 99%

Omalizumab (Xolair) in Children above 12 Years With Chronic Urticaria: A Review of Literature

Ghaffari¹,

Shahmohammadi²,

Ashrafi³

et al. 2015

J Pediatr Rev

View full text Add to dashboard Cite

Generally, 15-25% of general population experience urticaria during their life. The prevalence of chronic urticaria is about 0.1-0.3% in children and most often occurs between ages of 6-11 years. There are several causes for development of chronic urticaria. Known etiologies of chronic urticaria in children vary from 21% to 83%. Chronic urticaria caused by infections is more common in children than adults. Diagnosis of chronic urticaria is based on clinical history and physical examination and routine laboratory testing in the absence of a clinical history is rarely helpful. Similar to adults, antihistamines are the first line of treatment. Omalizumab as a biological engineering molecule is a recombinant humanized monoclonal antibody, which targets the CH3 domain of the ε chain of the free IgE. Omalizumab has been used in patients with H1-antihistamine-refractory chronic idiopathic urticaria (CIU). Here in we made a review about possible mechanisms by which omalizumab may be effective in children above 12 years with chronic urticaria, and also focused on its therapeutic effects, onset criteria and possible side effects.

show abstract

“…Idiopathic urticaria constitutes approximately 80% of all cases of chronic urticaria (3,11). After idiopathic urticaria physical urticaria is the second most frequently observed urticaria.…”

Section: Classificationmentioning

confidence: 99%

Çocukluk çağında ürtiker ve anjiyoödem: patojenez, tanı ve tedavi

Barlan¹,

Barış²

2012

Tpa

View full text Add to dashboard Cite

Review Sum maryUrticarial disease is characterized by transient erythematous, swelling and pruritic lesions. Classification of the disease as acute and chronic urticeria provide a comprehensive approach to detect the etiological factors and estimate the prognosis. In this paper, clinical classification of urticeria, pathogenesis, related factors with disease and therapy options were reviewed. (Turk Arch Ped 2012; 47: 232-236)

show abstract

An update on childhood urticaria and angioedema

Cited by 41 publications

References 44 publications

The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update

The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update

Omalizumab (Xolair) in Children above 12 Years With Chronic Urticaria: A Review of Literature

Çocukluk çağında ürtiker ve anjiyoödem: patojenez, tanı ve tedavi

Contact Info

Product

Resources

About